Title:
PHARMACEUTICAL COMPOSITION OF NATEGLINIDE AND ANOTHER ANTIDIABETCAGENT
Document Type and Number:
WIPO Patent Application WO2001021159
Kind Code:
A3
Abstract:
The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises nateglinide (I) or repaglinide and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), sulfonyl urea derivatives and metformin for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of diseases, especially metabolic disorders and in particular type 2 diabetes and diseases and conditions associated with diabetes; to a composition, respectively, which comprises nateglinide and a pharmaceutically acceptable carrier and to a process of making such composition; the use of such combination or composition for the preparation of a medicament for the prevention, delay of progression or treatment of metabolic disorders; a method of prevention, delay of progression or treatment of diseases in warm-blooded animals; the uses of such combination or composition for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight; and to a method of improving the bodily appearance of a warm-blooded animal.
More Like This:
| JP2019501136 | Designed bacterial composition |
| JP2005504717 | Treatment of dopamine-related dysfunction |
| JPH10287561 | SOLID PREPARATION COMPOUNDED WITH IBUPROFEN AND ITS PRODUCTION |
Inventors:
GATLIN MARJORIE REGAN (US)
BALL MICHELE (CH)
MANNION RICHARD OWEN (US)
KARNACHI ANEES ABDULQUADAR (US)
GUITARD CHRISTIANE (FR)
ALLISON MALCOLM (CH)
BALL MICHELE (CH)
MANNION RICHARD OWEN (US)
KARNACHI ANEES ABDULQUADAR (US)
GUITARD CHRISTIANE (FR)
ALLISON MALCOLM (CH)
Application Number:
PCT/EP2000/009074
Publication Date:
December 27, 2001
Filing Date:
September 15, 2000
Export Citation:
Assignee:
NOVARTIS AG (CH)
NOVARTIS ERFIND VERWALT GMBH (AT)
GATLIN MARJORIE REGAN (US)
BALL MICHELE (CH)
MANNION RICHARD OWEN (US)
KARNACHI ANEES ABDULQUADAR (US)
GUITARD CHRISTIANE (FR)
ALLISON MALCOLM (CH)
NOVARTIS ERFIND VERWALT GMBH (AT)
GATLIN MARJORIE REGAN (US)
BALL MICHELE (CH)
MANNION RICHARD OWEN (US)
KARNACHI ANEES ABDULQUADAR (US)
GUITARD CHRISTIANE (FR)
ALLISON MALCOLM (CH)
International Classes:
A61K9/20; A61K9/48; A61K31/195; A61K31/198; A61K31/425; A61K31/426; A61K31/44; A61K9/16; A61K31/4433; A61K31/4439; A61K31/63; A61K31/64; A61K38/28; A61K47/04; A61K47/12; A61K47/26; A61K47/32; A61K47/38; A61P1/00; A61P1/04; A61P3/00; A61P3/04; A61P3/10; A61P9/00; A61P9/10; A61P9/12; A61P13/12; A61P15/00; A61P15/10; A61P17/00; A61P19/02; A61P19/10; A61P27/06; A61P27/12; (IPC1-7): A61K38/13; A61K31/44; A61K31/425; A61K31/195; A61K31/64; A61K31/155; A61P3/00
Domestic Patent References:
| WO1998056378A1 | 1998-12-17 |
Foreign References:
| EP0749751A2 | 1996-12-27 | |||
| US4816484A | 1989-03-28 | |||
| US5463116A | 1995-10-31 |
Other References:
DUNNING B.E.: "Nateglinide: A glucose-sensitive insulinotropic agent that is chemically and pharmacologically distinct from the sulfonylureas.", CURRENT OPINION IN ENDOCRINOLOGY AND DIABETES, (1999) 6/SUPPL. 1 (S29-S31)., XP000997507
KARARA, ADEL H. (1) ET AL: "Lack of pharmacokinetic drug interaction between the antidiabetic agents A - 4166 and metformin.", PHARMACEUTICAL RESEARCH (NEW YORK), (NOV., 1997) VOL. 14, NO. 11 SUPPL., PP. S557. MEETING INFO.: ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS BOSTON, MASSACHUSETTS, USA NOVEMBER 2-6, 1997 AMERICAN ASSOCIATION OF PHARMACEUT, XP000997540
PERFETTI R ET AL: "NOVEL THERAPEUTIC STRATEGIES FOR THE TREATMENT OF TYPE 2 DIABETES", DIABETES/METABOLISM REVIEWS,US,WILEY, NEW YORK, NY, vol. 14, no. 3, 1998, pages 207 - 225, XP000908775, ISSN: 0742-4221
KARARA, ADEL H. (1) ET AL: "Lack of pharmacokinetic drug interaction between the antidiabetic agents A - 4166 and metformin.", PHARMACEUTICAL RESEARCH (NEW YORK), (NOV., 1997) VOL. 14, NO. 11 SUPPL., PP. S557. MEETING INFO.: ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS BOSTON, MASSACHUSETTS, USA NOVEMBER 2-6, 1997 AMERICAN ASSOCIATION OF PHARMACEUT, XP000997540
PERFETTI R ET AL: "NOVEL THERAPEUTIC STRATEGIES FOR THE TREATMENT OF TYPE 2 DIABETES", DIABETES/METABOLISM REVIEWS,US,WILEY, NEW YORK, NY, vol. 14, no. 3, 1998, pages 207 - 225, XP000908775, ISSN: 0742-4221
Download PDF: